[{"id":"1805ea50-70a8-4f38-a983-2031dc6b40df","acronym":"NICE-COMBO","url":"https://clinicaltrials.gov/study/NCT03864575","created_at":"2021-01-18T19:03:48.254Z","updated_at":"2024-07-02T16:36:58.189Z","phase":"Phase 2","brief_title":"An Open Label Phase II Study Combining Nivolumab and Celecoxib in Patients With Advanced \" Cold \" Solid Tumors","source_id_and_acronym":"NCT03864575 - NICE-COMBO","lead_sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","biomarkers":" BRAF • IDO1","pipe":" | ","alterations":" BRAF mutation • IDO1 expression • IDO1 positive","tags":["BRAF • IDO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • IDO1 expression • IDO1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • celecoxib oral"],"overall_status":"Unknown status","enrollment":" Enrollment 68","initiation":"Initiation: 08/15/2019","start_date":" 08/15/2019","primary_txt":" Primary completion: 06/15/2021","primary_completion_date":" 06/15/2021","study_txt":" Completion: 06/15/2021","study_completion_date":" 06/15/2021","last_update_posted":"2019-07-12"}]